SCHEMBL7092337

SCHEMBL7092337

c1ccc(-c2ccc(OCCCN3CCCC3)cc2)nc1

nearest known ligand 0.69

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 14/20 0.69
KCNH2 Q12809 2/20 0.68
HRH1 P35367 1/20 0.68
CYP1A2 P05177 1/20 0.62
CYP2D6 P10635 1/20 0.62
CYP19A1 P11511 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
ATP4A P20648 4/20 0.61
ATP4B P51164 4/20 0.61
HRH4 Q9H3N8 1/20 0.60
LTA4H P09960 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4094594 0.82 HRH3 (1.00) HRH3KCNH2HRH1HRH4LTA4H
SCHEMBL12050718 0.82 HRH3 (0.96) HRH3KCNH2HRH1HRH4LTA4H
SCHEMBL2885124 0.82 HRH3 (0.53) HRH3KCNH2HRH1ATP4AATP4B
SCHEMBL12017606 0.81 HRH3 (0.72) HRH3KCNH2HRH1
SCHEMBL491626 0.81 HRH3 (1.00) HRH3KCNH2HRH1HRH4LTA4H
SCHEMBL4094339 0.80 HRH3 (1.00) HRH3KCNH2HRH1HRH4
SCHEMBL12050645 0.80 HRH3 (1.00) HRH3KCNH2HRH1HRH4
SCHEMBL6847832 0.80 CYP1A2 (0.58) HRH3KCNH2HRH1CYP1A2CYP2D6
SCHEMBL5214535 0.79 HRH3 (0.57) HRH3KCNH2CYP1A2CYP2D6CYP19A1
SCHEMBL492205 0.78 HRH3 (0.84) HRH3KCNH2HRH1HRH4LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1301480-A1 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2003-04-16 EP disclosed
WO-2002006223-A1 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2002-01-24 WO disclosed